Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rocket Pharmaceuticals, Inc.

2.90
+0.02000.69%
Post-market: 2.87-0.0266-0.92%16:55 EDT
Volume:1.75M
Turnover:5.09M
Market Cap:312.44M
PE:-1.11
High:2.96
Open:2.91
Low:2.85
Close:2.88
Loading ...

Rocket Pharmaceuticals Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
28 May

Rocket Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $8 From $37

THOMSON REUTERS
·
28 May

Gene Therapy Death Worsens Picture for an Already Troubled Field -- Barrons.com

Dow Jones
·
28 May

TD Cowen Downgrades Rocket Pharmaceuticals to Hold From Buy

MT Newswires Live
·
27 May

Rocket Pharmaceuticals Cut to Hold From Buy by Needham

Dow Jones
·
27 May

J.P. Morgan Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
27 May

Needham downgrades Rocket Pharmaceuticals (RCKT) to a Hold

TIPRANKS
·
27 May

Rocket Pharmaceuticals Inc : Wedbush Cuts Target Price to $16 From $32

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals price target lowered to $16 from $32 at Wedbush

TIPRANKS
·
27 May

Rocket Pharmaceuticals Shares Down 56.5% After Patient Dies in Mid-Stage Gene Therapy Trial; FDA Puts Clinical Hold

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Exec Says the Patient Who Experienced the Serious Adverse Event Was Treated in Early May - Conf Call

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Shares Down as Trial Patient Dies of Complications

Dow Jones
·
27 May

Rocket Pharmaceuticals announces serious adverse event in RP-A501 trial

TIPRANKS
·
27 May

Rocket Pharmaceuticals Shares Down 52% Premarket After Patient Dies in Mid-Stage Gene Therapy Trial; FDA Puts Clinical Hold

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of Rp-a501 for Danon Disease

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - in Active Dialogue With FDA After Sae in Rp-a501 Trial

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - Expects Resources to Fund Operations Into 2027

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - Patient in Rp-a501 Phase 2 Trial Experiences Serious Adverse Event

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - Unable to Provide Guidance on Anticipated Timing for Completion of Phase 2 Trial

THOMSON REUTERS
·
27 May

Rocket Pharmaceuticals Inc - FDA Places Clinical Hold on Rp-a501 Trial After Sae

THOMSON REUTERS
·
27 May